American Trust Sells 205 Shares of Natera, Inc. (NASDAQ:NTRA)

American Trust lowered its position in Natera, Inc. (NASDAQ:NTRA) by 6.4% in the third quarter, Holdings Channel.com reports. The fund owned 3,003 shares of the medical research company’s stock after selling 205 shares during the period. American Trust’s holdings in Natera were worth $381,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Chartwell Investment Partners LLC increased its stake in Natera by 37.9% in the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after acquiring an additional 11,362 shares during the period. Cerity Partners LLC boosted its holdings in Natera by 27.0% during the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after purchasing an additional 18,316 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its stake in shares of Natera by 50.6% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 13,622 shares of the medical research company’s stock valued at $1,475,000 after purchasing an additional 4,575 shares during the period. Jag Capital Management LLC lifted its position in shares of Natera by 8.8% during the 3rd quarter. Jag Capital Management LLC now owns 175,590 shares of the medical research company’s stock worth $22,291,000 after buying an additional 14,159 shares during the period. Finally, First Turn Management LLC acquired a new stake in Natera in the 3rd quarter valued at $19,760,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of analyst reports. Leerink Partners lifted their price objective on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. TD Cowen boosted their price target on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Craig Hallum raised their price objective on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Canaccord Genuity Group lifted their target price on shares of Natera from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, JPMorgan Chase & Co. increased their price target on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $147.50.

Natera Stock Up 0.1 %

Shares of NASDAQ NTRA opened at $166.55 on Friday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $21.99 billion, a PE ratio of -94.63 and a beta of 1.63. The firm’s 50-day moving average is $144.02 and its 200-day moving average is $124.46. Natera, Inc. has a 1 year low of $57.22 and a 1 year high of $175.63.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business’s quarterly revenue was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.95) EPS. Equities analysts expect that Natera, Inc. will post -1.61 EPS for the current year.

Insider Buying and Selling at Natera

In related news, Director Rowan E. Chapman sold 1,767 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $170.24, for a total value of $300,814.08. Following the completion of the sale, the director now owns 6,202 shares in the company, valued at $1,055,828.48. This represents a 22.17 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven Leonard Chapman sold 5,024 shares of Natera stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $128.48, for a total value of $645,483.52. Following the transaction, the chief executive officer now owns 195,686 shares in the company, valued at approximately $25,141,737.28. This represents a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 137,987 shares of company stock valued at $21,895,591. 7.60% of the stock is currently owned by company insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.